Clinical Trial Update: Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery [Phase 2]

View source ↗

Summary

Novartis-sponsored Phase 2 trial evaluating BGG492 in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgery has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Seizures

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis | Conditions: Seizures, Epilepsy | Phase 2 | Status: COMPLETED